Tamoxifen and Exemestane Adjuvant Multicenter Trial An open label, randomized multicenter comparative trial of 5 years adjuvant Exemestane treatment versus Tamoxifen for 2½-3 years followed by 2½-2 years of Exemestane, for a total of 5 years as adjuvant treatment in Postmenopausal Women with Early Breast Cancer
Indication
Adjuvant
Subindication
Any HER2, HR+
Target sample size
8740
Actual accrual
9875
Date: 23/01/2006
Contact
Sponsor
LUMC Heelkunde (NL); Pfizer (intl)
Principal Investigator(s)
C.J.H. van de Velde, J.W.R. Nortier, C. Seynaeve, L. Beex
Study manager
E. Meershoek-Klein Kranenbarg
Central datamanagement and randomization
Leiden University Medical Center
Datacenter Surgery K6-R
P.O. Box 9600, 2300 RC Leiden
Phone +31 71 526 3500
Fax +31 71 526 6744
Design
Randomization: ArmA: exemestane (25 mg once daily) for 5 years Arm B: tamoxifen (20 mg once daily) for 2½-3 years followed by 2½-2 years of exemestane (25 mg once daily).
Objectives
To determine whether up- front adjuvant treatment with exemestane compared with adjuvant tamoxifen improves the relapse- free survival (RFS) of postmenopausal, receptor positive, early breast cancer patients following 2¾ (2½ -3) years of treatment.
Endpoints
Primary endpoint:
Relapse Free Survival (RFS) at 2¾ years
Secondary Endpoints:
RFS at 5 years;
Overall survival (OS); Incidence of second breast cancer (in contralateral breast);
Safety and long-term tolerability of the regimens
Eligibility Criteria
Female Postmenopausal ER and/or PR+ T > 3 cm or N+ or T < 3 cm, N0 but MAI >10 or BR grade 3 or adj therapy acccording to Ducth guidelines